IPCALAB2020-07-012020-09-30in-bse-fin:OneOperatingExpenses01Member IPCALAB2020-07-012020-09-30in-bse-fin:FourOperatingExpenses01Member IPCALAB2020-07-012020-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IPCALAB2020-07-012020-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member IPCALAB2020-07-012020-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member IPCALAB2020-07-012020-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member IPCALAB2020-07-012020-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member IPCALAB2020-07-012020-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares IPCALAB 2020-04-01 2021-03-31 2020-10-27 INR Crores Half yearly true Cash Flow Indirect Single segment Pharmaceuticals 2020-07-01 2020-09-30 Unaudited Standalone 12977700000.00 150000000.00 13127700000.00 4057800000.00 327800000.00 -320000000.00 2390900000.00 18100000.00 462600000.00 2919600000.00 9856800000.00 3270900000.00 0.00 3270900000.00 521000000.00 -6900000.00 514100000.00 0.00 2756800000.00 0.00 0.00 0.00 0.00 2756800000.00 -3200000.00 2753600000.00 0.00 0.00 253700000.00 2 21.79 21.79 0.00 0.00 21.79 21.79 1.tThe above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 7, 2020.The Statutory Auditors have carried out the limited review of the results. n n2.tThe Board has allotted on September 2, 2020, 5,00,000 fully paid-up equity shares of Rs. 2/- each @ Rs. 955/- per share upon conversion of warrants issued on November 7, 2019. n n3.tThe Board has declared an interim dividend of Rs. 8/- per share (400%), for which November 17, 2020 has been fixed as the record date for members' entitlement of interim dividend. n n4.tBeing manufacturers of pharmaceuticals and providers of essential services, the Company is continuing with its manufacturing and marketing operations strictly following the Covid-19 related guidelines issued by the government from time to time. The Company has considered possible impact of Covid-19 on the carrying amounts of property, plant and equipments, investments, inventories, receivables and other current assets. The Company expects that the carrying amounts of the assets are recoverable and that the Company will continue to have sufficient liquidity to finance its business operations as well as expansion plans. However, a definitive assessment of Covid-19 impact, at this stage, is not possible in view of uncertain economic environment. n n5.tThe Company has only one operating segment viz. 'Pharmaceuticals'. n n6.tFigures of the previous periods have been regrouped wherever necessary. Single segment 2020-04-01 2020-09-30 Unaudited Standalone 27830200000.00 266800000.00 28097000000.00 7685100000.00 661500000.00 -206600000.00 4810100000.00 42700000.00 914900000.00 5399000000.00 19306700000.00 8790300000.00 0.00 8790300000.00 1536000000.00 -38900000.00 1497100000.00 0.00 7293200000.00 0.00 0.00 0.00 0.00 7293200000.00 -12700000.00 7280500000.00 0.00 0.00 253700000.00 2 57.69 57.69 0.00 0.00 57.69 57.69 Other Expenses 2919600000.00 Other Expenses 5399000000.00 42700000.00 -578300000.00 -407300000.00 0.00 251600000.00 20100000.00 33200000.00 -375700000.00 0.00 144700000.00 0.00 -599500000.00 -500000.00 914900000.00 158400000.00 -26000000.00 48200000.00 -3600000.00 0.00 -172100000.00 0.00 159600000.00 0.00 -2000000.00 0.00 21100000.00 0.00 4400000.00 0.00 -685300000.00 8105000000.00 0.00 0.00 0.00 1006500000.00 0.00 7098500000.00 0.00 0.00 0.00 312300000.00 0.00 0.00 0.00 0.00 12400000.00 1263300000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 167300000.00 0.00 0.00 0.00 0.00 75600000.00 0.00 -3558700000.00 0.00 -5213600000.00 0.00 0.00 358100000.00 0.00 0.00 0.00 0.00 0.00 0.00 978100000.00 8200000.00 28700000.00 1600000.00 34900000.00 0.00 0.00 -693400000.00 1191500000.00 0.00 1191500000.00 2720700000.00 3912200000.00